.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,715,623

« Back to Dashboard

Claims for Patent: 8,715,623

Title:Pulmonary delivery of aminoglycoside
Abstract: A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.
Inventor(s): Tarara; Thomas E. (Burlingame, CA), Weers; Jeffry G. (Half Moon Bay, CA), Venthoye; Geraldine (Foster City, CA)
Assignee: Novartis AG (Basel, CH)
Application Number:11/981,986
Patent Claims: 1. A dispersible powder composition comprising particles comprising an aminoglycoside and a phospholipid for delivery to the lungs by inhalation, wherein the particles have a geometric diameter of less than 5 microns, the composition being effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses, and wherein each respirable unit dose comprises a volume of 0.30 to 0.95 ml.

2. A composition according to claim 1 wherein the composition comprises from about 50% to about 99% by weight aminoglycoside.

3. A composition according to claim 2 wherein the particles further comprise calcium chloride.

4. A composition according to claim 1 wherein the respirable unit dose is provided in a capsule, the capsule comprising hydroxypropylmethylcellulose.

5. A composition according to claim 1 wherein the particles have a bulk density of between 0.08 and 0.20 g/cm.sup.3.

6. A composition according to claim 1 wherein each respirable unit dose comprises a fill mass of between 25 and 50 mg, and said fill mass comprises between about 14-35 mg of aminoglycoside or salt thereof.

7. A composition according to claim 1 wherein the particles have a mass median aerodynamic diameter less than 5 microns.

8. A composition according to claim 1 having a pH of between 7 and 10.

9. A composition according to claim 1 wherein each respirable unit dose comprises a volume equivalent to a size #00 capsule or smaller capsule size.

10. A composition according to claim 1 wherein each respirable unit dose comprises a volume equivalent to a size #2 capsule or smaller capsule size.

11. A composition according to claim 1 wherein the aminoglycoside comprises tobramycin or salt thereof.

12. A composition according to claim 1 comprising calcium.

13. A composition according to claim 1 wherein the particles are spray dried particles.

14. A composition according to claim 1 wherein each respirable unit dose comprises 10-60 mg of aminoglycoside or salt thereof.

15. A composition according to claim 1 wherein the aminoglycoside comprises one or more of gentamicin, netilmicin, paramecin, tobramycin, amikacin, kanamycin, neomycin, and streptomycin.

16. A composition according to claim 1 wherein the particles have a moisture content of less than 15% by weight.

17. A composition according to claim 1 wherein the composition provides therapeutically effective therapy via administration of less than 5 respirable unit doses comprising the composition.

18. A method for administering a composition, the method comprising administering by inhalation less than 6 respirable unit doses of the composition according to claim 1 to provide at least 27.6 mg of aminoglycoside to the lungs.

19. A method for treating cystic fibrosis, the method comprising administering a pharmacologically effective amount of aminoglycoside comprising tobramycin to the lungs from a respirable unit dose according to claim 1.

20. A method for administering aminoglycoside to reduce the potential for development of bacteria in the lungs, the method comprising administering a pharmacologically effective amount of aminoglycoside to the lungs from a respirable unit dose according to claim 1.

21. A capsule comprising a composition for delivery of aminoglycoside to the lungs by inhalation, the composition including particles comprising phospholipid and aminoglycoside, the aminoglycoside comprising tobramycin, a geometric diameter less than 5 microns, a mass median aerodynamic diameter less than 5 microns, and a bulk density of greater than 0.08 g/cm.sup.3, wherein the capsule comprises a volume that is equivalent to, or less than, a capsule volume corresponding to a size #2 capsule, and wherein the capsule contains aminoglycoside or salt thereof, in an amount of 10-60 mg, whereby an effective dose of the aminoglycoside can be administered to the lungs using less than 6 capsules.

22. A pulmonary delivery method comprising administering a pharmacologically effective amount of tobramycin to the lungs by providing a composition comprising particles dispersed from less than 6 capsules by an inhalation device, the particles comprising a matrix of phospholipid and; tobramycin or a salt thereof, a bulk density of greater than 0.08 g/cm.sup.3, and having a pH of 7 or higher, wherein an effective amount of the tobramycin can be administered to the lungs in less than 6 respirable unit doses.

23. A dispersible powder composition comprising particles comprising phospholipid and tobramycin or salt thereof, the particles characterized by a geometric diameter of less than 5 microns, a mass median aerodynamic diameter of less than 5 microns, and a bulk density of between 0.08 g/cm.sup.3 and 0.20 g/cm.sup.3, wherein the amount of tobramycin or salt thereof in the particles is from about 50% to about 99%, wherein the composition is in the form of a unit dose containing the tobramycin or salt thereof in an amount of 10-60 mg, wherein a therapeutic dose of the tobramycin or salt thereof can be administered to the lungs in less than 6 respirable unit doses, each unit dose comprising a volume of 0.30 mL to 0.95 mL.

24. A respirable unit dose according to claim 23 comprising a volume equivalent to a size #0 capsule or less.

25. A composition according to claim 1 wherein the particles are hollow and porous.

26. A composition according to claim 1 wherein each respirable unit dose comprises an emitted dose greater than 70%.

27. A composition according to claim 1 wherein the particles have a bulk density of less than 0.20 g/cm.sup.3.

28. A method according to claim 22 wherein the particles comprise tobramycin or salt thereof in a potency of greater than 60%.

29. A method according to claim 22 wherein at least 27.6 mg of the tobramycin or salt thereof can be administered to the lungs in less than 6 respirable doses.

30. A composition according to claim 23 wherein the unit dose comprises a volume of less than 0.68 mL.

31. A composition according to claim 23 wherein the unit dose is contained in a size 2 capsule.

32. A composition according to claim 23 wherein the particles further comprise calcium chloride.

33. A composition according to claim 23 wherein the particles are hollow and porous.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc